A form of immunotherapy gaining ground as a way to treat childhood food allergies has shown promise in treating another rising scourge of children and young adults: Type 1 diabetes.

The DQ8-insulinB structure does not resolve the question of whether high risk of type 1 diabetes results directly from DQ8 presentation of a peptide from an autoantigen 2, although the overall ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated on a GLP-1 receptor agonist candidate for diabetes and obesity treatment.

Background Musculotendinous overuse injuries are prevalent in people with type 2 diabetes. Non-enzymatic glycosylation of collagen resulting in tendon stiffening may play a role. In this case–control ...

In the new study, which was published Thursday (Oct. 31) in the journal Cell, scientists took fat cells from a patient with type 1 diabetes and used chemicals to revert them back into "pluripotent ...

A chemical produced by the same cells that make insulin in the pancreas prevented and even reversed Type 1 diabetes in mice, researchers at St. Michael's Hospital have found.

For patients with type 1 diabetes (T1D), the very drug on which their life depends - injectable insulin - can create complications. Utah Science Technology and Research (USTAR) initiative has launched ...

See Structure of a human insulin peptide–HLA-DQ8 complex and susceptibility to type 1 diabetes by Kon Ho Lee. K. H. Lee et al. Nature Immunology 2, 501–507 (2001).